Assessment of fibrinolytic markers in patients with deep vein thrombosis

被引：5

作者：

Sharma, Saniya ^{[1
]}

Uppal, Varun ^{[1
]}

Senee, Hari Kishan ^{[1
]}

Ahluwalia, Jasmina ^{[1
]}

Das, Reena ^{[1
]}

Varma, Neelam ^{[1
]}

Malhotra, Pankaj ^{[2
]}

Kumar, Narender ^{[1
]}

机构：

[1] Postgrad Inst Med Educ & Res, Dept Hematol, Level 5,Res Block A,Sect 12, Chandigarh 160012, Punjab, India

[2] Nehru Hosp, Postgrad Inst Med Educ & Res, Dept Internal Med, Level 4, Chandigarh, Punjab, India

来源：

BLOOD COAGULATION & FIBRINOLYSIS | 2022年 / 33卷 / 02期

关键词：

alpha-2; antiplasmin; deep vein thrombosis; fibrinolysis; inherited hypercoagulability; plasminogen; plasminogen activator inhibitor; thrombin-activable fibrinolysis inhibitor; tissue plasminogen activator; VENOUS THROMBOSIS; PLASMINOGEN-ACTIVATOR; PLASMA-LEVELS; RISK-FACTOR; INHIBITOR; GENE; TAFI; HYPOFIBRINOLYSIS; ATHEROSCLEROSIS; DISEASE;

D O I：

10.1097/MBC.0000000000001114

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The association of the fibrinolytic markers with deep vein thrombosis (DVT) is still a matter of debate. The present study aimed to investigate the association between fibrinolytic markers and DVT. This observational study recruited 52 adult cases with lower limb DVT and 52 healthy adult volunteers as controls. The quantitative determination of plasminogen activator inhibitor-1 (PAH), plasminogen, thrombin activable fibrinolysis inhibitor (TAFI), tissue plasminogen activator (tPA) and a2antiplasmin (a2-AP) was performed by ELISA. TAFI, plasminogen and t-PA were significantly higher in cases than controls and PAI-1 was significantly lower in cases than controls. In addition, TAFI, plasminogen and t-PA levels were significantly increased in unprovoked and idiopathic DVT cases than controls. The present study suggests that the fibrinolytic markers tested in patients with a remote history of DVT are different than in individuals with no history of DVT and, with further study, may prove useful as screening assays for DVT risk. Copyright (C) 2021 Wolters Kluwer Health, Inc. All rights reserved.

引用

页码：113 / 118

页数：6

共 29 条

[1] Crowther MA, 2001, THROMB HAEMOSTASIS, V85, P390
[2] Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism
Eichinger, S
Schönauer, V
Weltermann, A
Minar, E
Bialonczyk, C
Hirschl, M
Schneider, B
Quehenberger, P
Kyrle, PA
[J]. BLOOD, 2004, 103 (10) : 3773 - 3776
[3] Flores J, 2003, ARCH PATHOL LAB MED, V127, P310
[4] Prospective study of fibrinolytic markers and venous thromboembolism
Folsom, AR
Cushman, M
Heckbert, SR
Rosamond, WD
Aleksic, N
[J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 2003, 56 (06) : 598 - 603
[5] Prospective study of fibrinolytic factors and incident coronary heart disease - The Atherosclerosis Risk in Communities (ARIC) Study
Folsom, AR
Aleksik, N
Park, E
Salomaa, V
Juneja, H
Wu, KK
[J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2001, 21 (04) : 611 - 617
[6] GRAM J, 1985, THROMB HAEMOSTASIS, V54, P503
[7] How we diagnose and treat deep vein thrombosis
Hirsh, J
Lee, AYY
[J]. BLOOD, 2002, 99 (09) : 3102 - 3110
[8] HOLVOET P, 1986, THROMB HAEMOSTASIS, V56, P124
[9] Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH
Kearon, C.
Ageno, W.
Cannegieter, S. C.
Cosmi, B.
Geersing, G-J.
Kyrle, P. A.
[J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2016, 14 (07) : 1480 - 1483
[10] Regression of proximal deep venous thrombosis is associated with fibrinolytic enhancement
Killewich, LA
Macko, RF
Cox, K
Franklin, DR
Benjamin, ME
Lilly, MP
Flinn, WR
[J]. JOURNAL OF VASCULAR SURGERY, 1997, 26 (05) : 861 - 868

← 1 2 3 →